Global Hemophilia Gene Therapy Market Analysis and Forecast 2024-2030
Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
According to APO Research, The global Hemophilia Gene Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Includes
This report presents an overview of global market for Hemophilia Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hemophilia Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Hemophilia Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hemophilia Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Hemophilia Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Hemophilia Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure and Freeline Therapeutics, etc.
Hemophilia Gene Therapy segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Hemophilia Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Hemophilia Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
According to APO Research, The global Hemophilia Gene Therapy market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
Report Includes
This report presents an overview of global market for Hemophilia Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Hemophilia Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Hemophilia Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Hemophilia Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Hemophilia Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Hemophilia Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure and Freeline Therapeutics, etc.
Hemophilia Gene Therapy segment by Company
- Spark Therapeutics
- Ultragenyx
- Shire PLC
- Sangamo Therapeutics
- Bioverativ
- BioMarin
- uniQure
- Freeline Therapeutics
- Hemophilia A
- Hemophilia B
- Hemophilia A Gene Therapy
- Hemophilia B Gene Therapy
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Hemophilia Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Hemophilia Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Hemophilia Gene Therapy Market by Type
1.2.1 Global Hemophilia Gene Therapy Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Hemophilia A
1.2.3 Hemophilia B
1.3 Hemophilia Gene Therapy Market by Application
1.3.1 Global Hemophilia Gene Therapy Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Hemophilia A Gene Therapy
1.3.3 Hemophilia B Gene Therapy
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 HEMOPHILIA GENE THERAPY MARKET DYNAMICS
2.1 Hemophilia Gene Therapy Industry Trends
2.2 Hemophilia Gene Therapy Industry Drivers
2.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
2.4 Hemophilia Gene Therapy Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Hemophilia Gene Therapy Market Perspective (2019-2030)
3.2 Global Hemophilia Gene Therapy Growth Trends by Region
3.2.1 Global Hemophilia Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Hemophilia Gene Therapy Market Size by Region (2019-2024)
3.2.3 Global Hemophilia Gene Therapy Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Hemophilia Gene Therapy Revenue by Players
4.1.1 Global Hemophilia Gene Therapy Revenue by Players (2019-2024)
4.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2019-2024)
4.1.3 Global Hemophilia Gene Therapy Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Hemophilia Gene Therapy Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Hemophilia Gene Therapy Key Players Headquarters & Area Served
4.4 Global Hemophilia Gene Therapy Players, Product Type & Application
4.5 Global Hemophilia Gene Therapy Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Hemophilia Gene Therapy Market CR5 and HHI
4.6.2 Global Top 5 and 10 Hemophilia Gene Therapy Players Market Share by Revenue in 2023
4.6.3 2023 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier
5 HEMOPHILIA GENE THERAPY MARKET SIZE BY TYPE
5.1 Global Hemophilia Gene Therapy Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Hemophilia Gene Therapy Revenue by Type (2019-2030)
5.3 Global Hemophilia Gene Therapy Revenue Market Share by Type (2019-2030)
6 HEMOPHILIA GENE THERAPY MARKET SIZE BY APPLICATION
6.1 Global Hemophilia Gene Therapy Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Hemophilia Gene Therapy Revenue by Application (2019-2030)
6.3 Global Hemophilia Gene Therapy Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Spark Therapeutics
7.1.1 Spark Therapeutics Comapny Information
7.1.2 Spark Therapeutics Business Overview
7.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
7.1.5 Spark Therapeutics Recent Developments
7.2 Ultragenyx
7.2.1 Ultragenyx Comapny Information
7.2.2 Ultragenyx Business Overview
7.2.3 Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
7.2.5 Ultragenyx Recent Developments
7.3 Shire PLC
7.3.1 Shire PLC Comapny Information
7.3.2 Shire PLC Business Overview
7.3.3 Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
7.3.5 Shire PLC Recent Developments
7.4 Sangamo Therapeutics
7.4.1 Sangamo Therapeutics Comapny Information
7.4.2 Sangamo Therapeutics Business Overview
7.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
7.4.5 Sangamo Therapeutics Recent Developments
7.5 Bioverativ
7.5.1 Bioverativ Comapny Information
7.5.2 Bioverativ Business Overview
7.5.3 Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
7.5.5 Bioverativ Recent Developments
7.6 BioMarin
7.6.1 BioMarin Comapny Information
7.6.2 BioMarin Business Overview
7.6.3 BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
7.6.5 BioMarin Recent Developments
7.7 uniQure
7.7.1 uniQure Comapny Information
7.7.2 uniQure Business Overview
7.7.3 uniQure Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
7.7.5 uniQure Recent Developments
7.8 Freeline Therapeutics
7.8.1 Freeline Therapeutics Comapny Information
7.8.2 Freeline Therapeutics Business Overview
7.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
7.8.5 Freeline Therapeutics Recent Developments
8 NORTH AMERICA
8.1 North America Hemophilia Gene Therapy Revenue (2019-2030)
8.2 North America Hemophilia Gene Therapy Revenue by Type (2019-2030)
8.2.1 North America Hemophilia Gene Therapy Revenue by Type (2019-2024)
8.2.2 North America Hemophilia Gene Therapy Revenue by Type (2025-2030)
8.3 North America Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
8.4 North America Hemophilia Gene Therapy Revenue by Application (2019-2030)
8.4.1 North America Hemophilia Gene Therapy Revenue by Application (2019-2024)
8.4.2 North America Hemophilia Gene Therapy Revenue by Application (2025-2030)
8.5 North America Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
8.6 North America Hemophilia Gene Therapy Revenue by Country
8.6.1 North America Hemophilia Gene Therapy Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Hemophilia Gene Therapy Revenue by Country (2019-2024)
8.6.3 North America Hemophilia Gene Therapy Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Hemophilia Gene Therapy Revenue (2019-2030)
9.2 Europe Hemophilia Gene Therapy Revenue by Type (2019-2030)
9.2.1 Europe Hemophilia Gene Therapy Revenue by Type (2019-2024)
9.2.2 Europe Hemophilia Gene Therapy Revenue by Type (2025-2030)
9.3 Europe Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
9.4 Europe Hemophilia Gene Therapy Revenue by Application (2019-2030)
9.4.1 Europe Hemophilia Gene Therapy Revenue by Application (2019-2024)
9.4.2 Europe Hemophilia Gene Therapy Revenue by Application (2025-2030)
9.5 Europe Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
9.6 Europe Hemophilia Gene Therapy Revenue by Country
9.6.1 Europe Hemophilia Gene Therapy Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Hemophilia Gene Therapy Revenue by Country (2019-2024)
9.6.3 Europe Hemophilia Gene Therapy Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Hemophilia Gene Therapy Revenue (2019-2030)
10.2 China Hemophilia Gene Therapy Revenue by Type (2019-2030)
10.2.1 China Hemophilia Gene Therapy Revenue by Type (2019-2024)
10.2.2 China Hemophilia Gene Therapy Revenue by Type (2025-2030)
10.3 China Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
10.4 China Hemophilia Gene Therapy Revenue by Application (2019-2030)
10.4.1 China Hemophilia Gene Therapy Revenue by Application (2019-2024)
10.4.2 China Hemophilia Gene Therapy Revenue by Application (2025-2030)
10.5 China Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Hemophilia Gene Therapy Revenue (2019-2030)
11.2 Asia Hemophilia Gene Therapy Revenue by Type (2019-2030)
11.2.1 Asia Hemophilia Gene Therapy Revenue by Type (2019-2024)
11.2.2 Asia Hemophilia Gene Therapy Revenue by Type (2025-2030)
11.3 Asia Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
11.4 Asia Hemophilia Gene Therapy Revenue by Application (2019-2030)
11.4.1 Asia Hemophilia Gene Therapy Revenue by Application (2019-2024)
11.4.2 Asia Hemophilia Gene Therapy Revenue by Application (2025-2030)
11.5 Asia Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
11.6 Asia Hemophilia Gene Therapy Revenue by Country
11.6.1 Asia Hemophilia Gene Therapy Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Hemophilia Gene Therapy Revenue by Country (2019-2024)
11.6.3 Asia Hemophilia Gene Therapy Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Hemophilia Gene Therapy Revenue (2019-2030)
12.2 MEALA Hemophilia Gene Therapy Revenue by Type (2019-2030)
12.2.1 MEALA Hemophilia Gene Therapy Revenue by Type (2019-2024)
12.2.2 MEALA Hemophilia Gene Therapy Revenue by Type (2025-2030)
12.3 MEALA Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
12.4 MEALA Hemophilia Gene Therapy Revenue by Application (2019-2030)
12.4.1 MEALA Hemophilia Gene Therapy Revenue by Application (2019-2024)
12.4.2 MEALA Hemophilia Gene Therapy Revenue by Application (2025-2030)
12.5 MEALA Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
12.6 MEALA Hemophilia Gene Therapy Revenue by Country
12.6.1 MEALA Hemophilia Gene Therapy Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Hemophilia Gene Therapy Revenue by Country (2019-2024)
12.6.3 MEALA Hemophilia Gene Therapy Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Hemophilia Gene Therapy Market by Type
1.2.1 Global Hemophilia Gene Therapy Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Hemophilia A
1.2.3 Hemophilia B
1.3 Hemophilia Gene Therapy Market by Application
1.3.1 Global Hemophilia Gene Therapy Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Hemophilia A Gene Therapy
1.3.3 Hemophilia B Gene Therapy
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 HEMOPHILIA GENE THERAPY MARKET DYNAMICS
2.1 Hemophilia Gene Therapy Industry Trends
2.2 Hemophilia Gene Therapy Industry Drivers
2.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
2.4 Hemophilia Gene Therapy Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Hemophilia Gene Therapy Market Perspective (2019-2030)
3.2 Global Hemophilia Gene Therapy Growth Trends by Region
3.2.1 Global Hemophilia Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Hemophilia Gene Therapy Market Size by Region (2019-2024)
3.2.3 Global Hemophilia Gene Therapy Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Hemophilia Gene Therapy Revenue by Players
4.1.1 Global Hemophilia Gene Therapy Revenue by Players (2019-2024)
4.1.2 Global Hemophilia Gene Therapy Revenue Market Share by Players (2019-2024)
4.1.3 Global Hemophilia Gene Therapy Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Hemophilia Gene Therapy Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Hemophilia Gene Therapy Key Players Headquarters & Area Served
4.4 Global Hemophilia Gene Therapy Players, Product Type & Application
4.5 Global Hemophilia Gene Therapy Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Hemophilia Gene Therapy Market CR5 and HHI
4.6.2 Global Top 5 and 10 Hemophilia Gene Therapy Players Market Share by Revenue in 2023
4.6.3 2023 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier
5 HEMOPHILIA GENE THERAPY MARKET SIZE BY TYPE
5.1 Global Hemophilia Gene Therapy Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Hemophilia Gene Therapy Revenue by Type (2019-2030)
5.3 Global Hemophilia Gene Therapy Revenue Market Share by Type (2019-2030)
6 HEMOPHILIA GENE THERAPY MARKET SIZE BY APPLICATION
6.1 Global Hemophilia Gene Therapy Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Hemophilia Gene Therapy Revenue by Application (2019-2030)
6.3 Global Hemophilia Gene Therapy Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Spark Therapeutics
7.1.1 Spark Therapeutics Comapny Information
7.1.2 Spark Therapeutics Business Overview
7.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
7.1.5 Spark Therapeutics Recent Developments
7.2 Ultragenyx
7.2.1 Ultragenyx Comapny Information
7.2.2 Ultragenyx Business Overview
7.2.3 Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
7.2.5 Ultragenyx Recent Developments
7.3 Shire PLC
7.3.1 Shire PLC Comapny Information
7.3.2 Shire PLC Business Overview
7.3.3 Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
7.3.5 Shire PLC Recent Developments
7.4 Sangamo Therapeutics
7.4.1 Sangamo Therapeutics Comapny Information
7.4.2 Sangamo Therapeutics Business Overview
7.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
7.4.5 Sangamo Therapeutics Recent Developments
7.5 Bioverativ
7.5.1 Bioverativ Comapny Information
7.5.2 Bioverativ Business Overview
7.5.3 Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
7.5.5 Bioverativ Recent Developments
7.6 BioMarin
7.6.1 BioMarin Comapny Information
7.6.2 BioMarin Business Overview
7.6.3 BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
7.6.5 BioMarin Recent Developments
7.7 uniQure
7.7.1 uniQure Comapny Information
7.7.2 uniQure Business Overview
7.7.3 uniQure Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
7.7.5 uniQure Recent Developments
7.8 Freeline Therapeutics
7.8.1 Freeline Therapeutics Comapny Information
7.8.2 Freeline Therapeutics Business Overview
7.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (2019-2024)
7.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
7.8.5 Freeline Therapeutics Recent Developments
8 NORTH AMERICA
8.1 North America Hemophilia Gene Therapy Revenue (2019-2030)
8.2 North America Hemophilia Gene Therapy Revenue by Type (2019-2030)
8.2.1 North America Hemophilia Gene Therapy Revenue by Type (2019-2024)
8.2.2 North America Hemophilia Gene Therapy Revenue by Type (2025-2030)
8.3 North America Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
8.4 North America Hemophilia Gene Therapy Revenue by Application (2019-2030)
8.4.1 North America Hemophilia Gene Therapy Revenue by Application (2019-2024)
8.4.2 North America Hemophilia Gene Therapy Revenue by Application (2025-2030)
8.5 North America Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
8.6 North America Hemophilia Gene Therapy Revenue by Country
8.6.1 North America Hemophilia Gene Therapy Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Hemophilia Gene Therapy Revenue by Country (2019-2024)
8.6.3 North America Hemophilia Gene Therapy Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Hemophilia Gene Therapy Revenue (2019-2030)
9.2 Europe Hemophilia Gene Therapy Revenue by Type (2019-2030)
9.2.1 Europe Hemophilia Gene Therapy Revenue by Type (2019-2024)
9.2.2 Europe Hemophilia Gene Therapy Revenue by Type (2025-2030)
9.3 Europe Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
9.4 Europe Hemophilia Gene Therapy Revenue by Application (2019-2030)
9.4.1 Europe Hemophilia Gene Therapy Revenue by Application (2019-2024)
9.4.2 Europe Hemophilia Gene Therapy Revenue by Application (2025-2030)
9.5 Europe Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
9.6 Europe Hemophilia Gene Therapy Revenue by Country
9.6.1 Europe Hemophilia Gene Therapy Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Hemophilia Gene Therapy Revenue by Country (2019-2024)
9.6.3 Europe Hemophilia Gene Therapy Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Hemophilia Gene Therapy Revenue (2019-2030)
10.2 China Hemophilia Gene Therapy Revenue by Type (2019-2030)
10.2.1 China Hemophilia Gene Therapy Revenue by Type (2019-2024)
10.2.2 China Hemophilia Gene Therapy Revenue by Type (2025-2030)
10.3 China Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
10.4 China Hemophilia Gene Therapy Revenue by Application (2019-2030)
10.4.1 China Hemophilia Gene Therapy Revenue by Application (2019-2024)
10.4.2 China Hemophilia Gene Therapy Revenue by Application (2025-2030)
10.5 China Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Hemophilia Gene Therapy Revenue (2019-2030)
11.2 Asia Hemophilia Gene Therapy Revenue by Type (2019-2030)
11.2.1 Asia Hemophilia Gene Therapy Revenue by Type (2019-2024)
11.2.2 Asia Hemophilia Gene Therapy Revenue by Type (2025-2030)
11.3 Asia Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
11.4 Asia Hemophilia Gene Therapy Revenue by Application (2019-2030)
11.4.1 Asia Hemophilia Gene Therapy Revenue by Application (2019-2024)
11.4.2 Asia Hemophilia Gene Therapy Revenue by Application (2025-2030)
11.5 Asia Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
11.6 Asia Hemophilia Gene Therapy Revenue by Country
11.6.1 Asia Hemophilia Gene Therapy Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Hemophilia Gene Therapy Revenue by Country (2019-2024)
11.6.3 Asia Hemophilia Gene Therapy Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Hemophilia Gene Therapy Revenue (2019-2030)
12.2 MEALA Hemophilia Gene Therapy Revenue by Type (2019-2030)
12.2.1 MEALA Hemophilia Gene Therapy Revenue by Type (2019-2024)
12.2.2 MEALA Hemophilia Gene Therapy Revenue by Type (2025-2030)
12.3 MEALA Hemophilia Gene Therapy Revenue Share by Type (2019-2030)
12.4 MEALA Hemophilia Gene Therapy Revenue by Application (2019-2030)
12.4.1 MEALA Hemophilia Gene Therapy Revenue by Application (2019-2024)
12.4.2 MEALA Hemophilia Gene Therapy Revenue by Application (2025-2030)
12.5 MEALA Hemophilia Gene Therapy Revenue Share by Application (2019-2030)
12.6 MEALA Hemophilia Gene Therapy Revenue by Country
12.6.1 MEALA Hemophilia Gene Therapy Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Hemophilia Gene Therapy Revenue by Country (2019-2024)
12.6.3 MEALA Hemophilia Gene Therapy Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
